Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Cardiol. Jan 26, 2012; 4(1): 8-14
Published online Jan 26, 2012. doi: 10.4330/wjc.v4.i1.8
Table 3 Antithrombotic treatment at discharge in patients of the atrial fibrillation group who survived to hospital discharge (n = 15)
PatientAgeGenderCHA2DS2-VASCHAS-BLEDTreatment at dischargeFollow up (mo)Non-fatal eventsFollow up (mo)Survival
187Female65Warfarin2None2Alive
276Male44Aspirin32None32Alive
381Female53Warfarin + Aspirin7None7Alive
480Female43Warfarin1None1Alive
590Female62Warfarin26None26Alive
677Female53Warfarin23None23Alive
768Female22Aspirin + Clopidogrel10None10Alive
883Male74Warfarin + Aspirin3None3Death, non-cardiac
980Female32Warfarin19None19Alive
1079Female53Warfarin + Aspirin30Stroke31Death, non-cardiac
1184Female53Warfarin + Clopidogrel1Heart failure admission31Alive
1287Female42Warfarin + Aspirin6None6Alive
1383Female32Warfarin5None5Alive
1482Male33Warfarin + Aspirin2None2None
1568Male32Warfarin + Clopidogrel1Heart failure admission3Alive

  • Citation: Salinas P, Moreno R, Calvo L, Jiménez-Valero S, Galeote G, Sánchez-Recalde A, López-Fernández T, Garcia-Blas S, Iglesias D, Riera L, Moreno-Gómez I, Mesa JM, Plaza I, Ayala R, Gonzalez R, López-Sendón JL. Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation. World J Cardiol 2012; 4(1): 8-14
  • URL: https://www.wjgnet.com/1949-8462/full/v4/i1/8.htm
  • DOI: https://dx.doi.org/10.4330/wjc.v4.i1.8